SEARCH:   Advanced

Blood, 15 January 2007, Vol. 109, No. 2, pp. 471-477. Prepublished online as a Blood First Edition Paper on September 21, 2006; DOI 10.1182/blood-2006-07-032557. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-032557v1 109/2/471    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Choi, J. Articles by Ahn, H. S. Search for Related Content PubMed PubMed Citation Articles by Choi, J. Articles by Ahn, H. S. Related Collections Neoplasia Apoptosis Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia Jaewon Choi1, Yu Kyeong Hwang2, Ki Woong Sung1,, Soo Hyun Lee1, Keon Hee Yoo1, Hye Lim Jung1, Hong Hoe Koo1,, Hee-Jin Kim3, Hyong Jin Kang4, Hee Young Shin4, and Hyo Seop Ahn4 1 Department of Pediatrics, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, South Korea; 2 Division of Immunotherapy, Mogam Biotechnology Research Institute, Yongin, South Korea; 3 Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; 4 Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, South Korea Livin, a member of the inhibitor of apoptosis proteins, has been considered to be a poor prognostic marker in malignancies. However, little is known about the clinical relevance of Livin expression in childhood acute lymphoblastic leukemia (ALL). In this study, the expression of Livin was analyzed in 222 patients with childhood ALL using quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) to investigate a possible association with the clinical features at diagnosis and treatment outcomes. Both Livin expression rates and expression levels were higher in patients with favorable prognostic factors. The expression rate was also higher in patients with a favorable day 7 bone marrow response to induction chemotherapy (P < .001). The Livin expression was related to the absence of relapse (P < .001). Similarly, the relapse-free survival rate (± 95% CI) was higher in patients with Livin expression than in patients without Livin expression (97.9% ± 4.0% versus 64.9% ± 11.8%, P < .001). Multivariate analysis for relapse-free survival demonstrated that Livin expression was an independent favorable prognostic factor in childhood ALL (P = .049). This study suggests that Livin expression is a novel prognostic marker in childhood ALL and thus needs to be incorporated into the patient stratification and treatment protocols. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Livin: a proapoptotic factor in ALL? Ching-Hon Pui Blood 2007 109: 394-395. [Full Text] [PDF] This article has been cited by other articles: K. W. Sung, J. Choi, Y. K. Hwang, S. J. Lee, H.-J. Kim, S. H. Lee, K. H. Yoo, H. L. Jung, and H. H. Koo Overexpression of Apollon, an Antiapoptotic Protein, Is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2007; 13(17): 5109 - 5114. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020